Needham Downgrades Esperion Therapeutics to Hold

Benzinga Newsdesk www.benzinga.com Negative 86.7%

Neg 86.7% Neu 0% Pos 0%

Needham analyst Serge Belanger downgrades Esperion Therapeutics (NASDAQ:ESPR) from Buy to Hold.

Comments

No comments yet. Be the first!